Yüklüyor......
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
BACKGROUND: The HER2 extracellular domain shed in blood (HER2(ECD)) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2(ECD) values in patients with metastatic breast cancer treated in the SAKK22/99 trial compa...
Kaydedildi:
| Yayımlandı: | BMC Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7014942/ https://ncbi.nlm.nih.gov/pubmed/32046665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6594-0 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|